Breaking News

Dendreon Gains Approval for Atlanta Manufacturing Facility

To manufacture cancer treatment Provenge

Dendreon Corp. received approval from the FDA for its cancer immunotherapy manufacturing facility in Atlanta, GA for the production of Provenge (sipuleucel-T), a treatment for metastatic castrate resistant (hormone refractory) prostate cancer. The Atlanta facility includes 36 workstations. The company plans to bring these new workstations online in a staged approach. Along with NJ and CA facilities, Dendreon now has three facilities available to manufacture Provenge.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters